

ご関係者 各位

2023 年 6 月 20 日

島津ダイアグノスティクス株式会社

## 「Newsweek International」掲載のお知らせ

この度、政治や社会情勢などを扱うアメリカ合衆国の週刊誌「Newsweek International」2023 年 6 月 16 日号に、当社代表取締役社長執行役員 小野 徳哉のインタビュー記事が掲載されました。記事では、日本国内における検査薬事業と弊社の展望について述べております。



**Shimadzu Diagnostics: pioneering development in regenerative medicine and microbial testing**

Through its microbial testing kits and regenerative medicine solutions, Shimadzu Diagnostics is helping to tackle the greatest global health challenges.

"Innovation is not something that we can do in isolation. As such, we seek to expand our business lines and partnerships."

Tokuya Ono, President, Shimadzu Diagnostics Corp.

**CompactDry**

Following its establishment in 1935, Nissui Pharmaceutical sourced marine-based ingredients for medicinal and pharmaceutical purposes. Today, the company – which was renamed Shimadzu Diagnostics Corporation in April following its 100% takeover by Shimadzu Corporation – is a leader in the field of microbial testing kits and regenerative medicine solutions. The emergence of new strains of bacteria is one of the most serious

global health challenges. To tackle this issue, tracing where the resistant strains come from and identifying the root causes for resistance is of paramount importance. In response, Nissui developed Raisus S4, a fully automated rapid bacteria identification and antimicrobial susceptibility testing instrument using digital detection technology.

Another of the company's flagship microbial testing kits is Compact Dry, a ready-to-use culture media that is used in the detection of bacteria strains and the potential causes for food poisoning. "While other culture media require chilling between -2-5°C, CompactDry is a dry medium that can be transported without such

MSF-BM precautions," explains company president Tokuya Ono. With Japan leading the way in regenerative medicine, Shimadzu Diagnostics is supporting the fast-growing medical field with cell culture medium and testing solutions, including HYDROX, a three-dimensional cell culture substrate that allows the growth of different types of cells, and MSF-BM, a high-quality cell culture medium. "Since the cell culture business, particularly culture media and reagents, is part of our rich know-how, our strategy is to provide custom-made solutions in this field," says Mr. Ono.

**SHIMADZU**  
Excellence in Science  
corp.sdc.shimadzu.co.jp

また、英国の通信社「The Worldfolio」Web サイトにも、インタビューの全文が掲載されております。

The Worldfolio インタビュー全文 URL :

<https://www.theworldfolio.com/interviews/shimadzu-diagnostics-pioneering-regenerative-medicine-and-programmable-medical-devices-/5712/>

**Shimadzu Diagnostics: pioneering development in regenerative medicine and microbial testing**

Interview - June 10, 2023

*Through its microbial testing kits and regenerative medicine solutions, Shimadzu Diagnostics is helping to tackle the greatest global health challenges.*

【本件に関するお問い合わせ】

島津ダイアグノスティクス株式会社

コーポレート本部

〒110-8736 東京都台東区上野 3-24-6 上野フロンティアタワー20F

<https://corp.sdc.shimadzu.co.jp/>

\*お問い合わせについては、当社ホームページのお問い合わせフォームよりお願い申し上げます。

お問い合わせフォーム URL : <https://corp.sdc.shimadzu.co.jp/question/?mode=e>

以上